Wellington Shields & Co. LLC reduced its position in Pfizer, Inc. (NYSE:PFE) by 0.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 56,682 shares of the biopharmaceutical company’s stock after selling 194 shares during the period. Pfizer comprises 0.7% of Wellington Shields & Co. LLC’s holdings, making the stock its 24th largest position. Wellington Shields & Co. LLC’s holdings in Pfizer were worth $1,904,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Fisher Asset Management LLC lifted its stake in Pfizer by 3.9% in the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock valued at $1,143,248,000 after purchasing an additional 1,275,832 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Pfizer by 1.2% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock valued at $1,069,433,000 after purchasing an additional 377,404 shares during the last quarter. Macquarie Group Ltd. lifted its stake in Pfizer by 0.9% in the 1st quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock valued at $844,431,000 after purchasing an additional 228,405 shares during the last quarter. Boston Partners lifted its stake in Pfizer by 7.3% in the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock valued at $830,071,000 after purchasing an additional 1,649,801 shares during the last quarter. Finally, Bank of Montreal Can lifted its stake in Pfizer by 1.2% in the 2nd quarter. Bank of Montreal Can now owns 18,534,159 shares of the biopharmaceutical company’s stock valued at $622,562,000 after purchasing an additional 227,682 shares during the last quarter. Institutional investors and hedge funds own 69.00% of the company’s stock.

In related news, CEO Ian C. Read sold 197,168 shares of the stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the transaction, the chief executive officer now owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the transaction, the insider now directly owns 132,124 shares in the company, valued at approximately $4,492,216. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 464,521 shares of company stock worth $15,813,961. Corporate insiders own 0.06% of the company’s stock.

Several equities research analysts have issued reports on the stock. Berenberg Bank restated a “hold” rating and set a $36.00 price objective (down from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Jefferies Group LLC set a $37.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, September 18th. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, September 19th. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. Pfizer currently has an average rating of “Hold” and a consensus price target of $38.04.

Pfizer, Inc. (NYSE:PFE) traded down 0.56% during mid-day trading on Monday, hitting $35.76. 5,871,378 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $33.78 and its 200-day moving average price is $33.53. The stock has a market cap of $212.68 billion, a PE ratio of 26.16 and a beta of 1.00. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $36.21.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the company posted $0.64 EPS. Equities analysts expect that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.watchlistnews.com/pfizer-inc-pfe-position-cut-by-wellington-shields-co-llc/1587450.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.